Monte Rosa (NASDAQ: GLUE) CEO stock sale reported under 10b5-1 plan

Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported open-market sales of company common stock on January 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. He sold 3,707 shares at a weighted average price of $23.2422, 1,450 shares at $23.8762, and 309 shares at $24.5736, for a total of 5,466 shares sold.

The filing notes that each weighted average price reflects multiple trades, with sale prices ranging from $22.42 to $24.65. After these transactions, Warmuth beneficially owned 618,937 shares of Monte Rosa common stock in direct ownership.

Insider Trade Summary

Net Seller: 5,466 shares ($128,373)

Net Sell 3 txns

Insider Warmuth Markus

Role President & CEO

Sold 5,466 shs ($128K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,707	$23.2422	$86K
Sale	Common Stock	1,450	$23.8762	$35K
Sale	Common Stock	309	$24.5736	$8K

Holdings After Transaction: Common Stock — 620,696 shares (Direct)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.42 to $23.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.43 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warmuth Markus

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MA 02118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		S(1)		3,707	D	$23.2422(2)	620,696	D
Common Stock	01/07/2026		S(1)		1,450	D	$23.8762(3)	619,246	D
Common Stock	01/07/2026		S(1)		309	D	$24.5736(4)	618,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.42 to $23.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.43 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Markus Warmuth	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported the insider transaction in Monte Rosa Therapeutics (GLUE)?

The transaction was reported by Markus Warmuth, who serves as President, CEO, and a Director of Monte Rosa Therapeutics, Inc.

How many Monte Rosa (GLUE) shares did CEO Markus Warmuth sell?

On January 7, 2026, Markus Warmuth sold a total of 5,466 shares of Monte Rosa common stock in three separate transactions.

At what prices were the GLUE shares sold in this Form 4 filing?

The reported weighted average sale prices were $23.2422 for 3,707 shares, $23.8762 for 1,450 shares, and $24.5736 for 309 shares, with individual trades occurring between $22.42 and $24.65.

How many Monte Rosa (GLUE) shares does the CEO hold after these sales?

Following the reported transactions, Markus Warmuth beneficially owned 618,937 shares of Monte Rosa common stock directly.

Was the Monte Rosa CEO’s stock sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that these transactions were effected under a Rule 10b5-1 trading plan adopted on May 14, 2025, which is a pre-arranged plan for trading company stock.

What does the Form 4 say about the detailed price ranges of the GLUE share sales?

The filing explains that each weighted average price covers multiple trades, with shares sold in ranges of $22.42–$23.40, $23.43–$24.41, and $24.43–$24.65, and offers to provide full breakdowns upon request.